Group 1: Market Analysis - The Shanghai Composite Index is currently facing a resistance level at 3418 points and a support level at 3174 points, with the index closing at 3376 points on June 4, 2025, just 42 points away from the resistance level [5][6] - If the index effectively breaks above the 3418 points resistance, it may signal a shift from a long-term sideways trading range to an upward trend, with the 3418 points level becoming a strong support [5][6] - The index has attempted to break the 3418 points resistance five times since October 8, 2024, but has not succeeded, indicating significant market indecision [6] Group 2: Consumer Trends - During the Dragon Boat Festival, domestic tourism saw 119 million trips, a year-on-year increase of 5.7%, while tourism revenue reached 42.73 billion yuan, growing by 5.9% [9][10] - The average spending per person for domestic travel was 359.08 yuan, a slight decrease of 2.11% compared to the same period last year [9] - Short-distance and surrounding travel dominated, with nearly 50% of travelers opting for nearby destinations, and family trips being a significant trend due to the coinciding Children's Day [10][11] Group 3: Economic Indicators - The People's Bank of China announced a 1 trillion yuan reverse repurchase operation, indicating ongoing liquidity support in the market [16] - The tax authority reported that the private economy's vitality has been improving, with a 3.6% year-on-year increase in sales revenue for the private sector in the first four months of 2025, outpacing the overall growth of national enterprises [17][18] - The European Central Bank lowered interest rates by 25 basis points, reflecting a continued accommodative monetary policy stance in response to economic conditions [21]

Investment Rating - The industry investment rating is "Market Standard" indicating that the industry index is expected to perform within -10% to 10% relative to the CSI 300 index over the next six months [5]. Core Insights - The tourism sector is experiencing a slowdown in both visitor numbers and revenue growth, with domestic tourism during the Dragon Boat Festival seeing 119 million trips, a year-on-year increase of 5.7%, and tourism revenue reaching 42.73 billion yuan, up 5.9% year-on-year [4]. - Short-distance travel is the main trend, with nearly 50% of travelers opting for nearby destinations. Family trips, particularly for children, are a significant driver of travel during this period, with 90% of the top 50 scenic spots being family-oriented [4]. - The inbound tourism market is showing high growth, with 590.7 million people entering and exiting the country during the holiday, a 2.7% increase year-on-year, and 231,000 foreign visitors entering under visa-free policies, up 59.4% [4]. - Scenic spots like Changbai Mountain maintained visitor numbers but saw a 23.94% increase in revenue. Xiangyuan Cultural Tourism reported a 29.96% increase in visitors and a 25.27% increase in revenue during the holiday [4]. - Transportation sectors, particularly rail and road, showed higher growth rates, with cross-regional travel exceeding 653 million trips, a 2.5% increase year-on-year [4]. - Future consumption growth is anticipated due to new consumption trends, supportive policies, and the ongoing recovery of the tourism market, with a focus on OTA platforms and related sectors [4].

总 量 研 究 [Table_Reportdate] 2025年06月05日 [若有效上破 Table_NewTitle] 3418点压力位，指数或有进 一步盘升动能 策 略 研 究 [证券分析师 Table_Authors] 王洋 S0630513040002 wangyang@longone.com.cn [相关研究 Table_Report] 1.《波浪里前行 上证指数目前或处 于黎明的曙光中》 2.《上证指数或酝酿反弹动能——技 术分析上证指数系列》 3.《上证指数短线或有反弹需求—— 技术分析上证指数简评》 4.《上证指数或有进一步震荡盘升动 能——技术分析上证指数简评》 5.《上证指数短线技术条件明显修 复，回落空间小上涨空间大——技术 分析上证指数简评》 6.《证券板块技术条件有所向好，上 涨空间大回落空间小——技术分析 行业板块简评》 7.《保险板块或已走出下降趋势，上 涨空间大回落空间小——技术分析 行业板块简评》 [table_main] 投资要点 ➢ 核心观点：上证指数目前上有3418点一线的压力，下有3174点一线的支撑，目前尚未有效 突破。近日指数正趋近3418点一线的压力位，压力位 ...

[Table_Reportdate] 2025年06月05日 [证券分析师： Table_Authors] 张季恺 S0630521110001 zjk@longone.com.cn 证券分析师： 王洋 S0630513040002 wangyang@longone.com.cn 证券分析师： 刘思佳 S0630516080002 liusj@longone.com.cn 联系人： 花雨欣 hyx@longone.com.cn [晨会纪要 Table_NewTitle] 20250605 [table_summary] 重点推荐 财经要闻 晨 会 纪 要 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 ➢ 1.英伟达Q1数据中心业务成绩亮眼，美限制EDA龙头对华提供服务——电子行业周报 2025/5/26-2025/6/1 ➢ 2.关注陆家嘴论坛政策发布预期带来的市场情绪催化——非银金融行业周报（20250526- 20250601） ➢ 1.四部门组织开展人力资源服务业与制造业融合发展试点工作 ➢ 2.美国ISM服务业PMI大幅回落，跌至50荣枯线以下 ...

[Table_Reportdate] 2025年06月04日 ➢ 1.创新药密集上市，关注后续医保谈判————医药生物行业周报（2025/05/26- 2025/06/01） ➢ 2.供给端扰动背景下，关注相关化工板块配置机会——基础化工行业周报（2025/05/26- 2025/06/01） ➢ 3.白酒持续筑底，重视新消费趋势——食品饮料行业周报（2025/5/26-2025/6/1） ➢ 4.轨交设备板块业绩改善，关注后续铁路固定资产投资进展——机械设备行业周报 （20250526-20250601） 张季恺 S0630521110001 zjk@longone.com.cn 证券分析师： 王洋 S0630513040002 wangyang@longone.com.cn 证券分析师： 刘思佳 S0630516080002 liusj@longone.com.cn 联系人： 花雨欣 hyx@longone.com.cn [晨会纪要 Table_NewTitle] 20250604 重点推荐 财经要闻 晨 会 纪 要 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的 ...

Investment Rating - The report assigns an "Overweight" rating for the food and beverage industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [1][53]. Core Insights - The food and beverage sector experienced a decline of 1.06% last week, slightly outperforming the CSI 300 index by 0.02 percentage points, ranking 27th among 31 sectors [4][9]. - The liquor segment is in a bottoming phase, with a focus on leading companies for recovery. The impact of recent "alcohol bans" is expected to be limited, as business banquets and personal consumption remain the primary drivers of demand [4][9]. - The beer sector is showing signs of improvement as the peak consumption season approaches, with April production figures indicating a 4.8% year-on-year increase [4][23]. - The snack segment is characterized by high growth potential, driven by strong product categories and new distribution channels [4]. - The dairy sector is expected to stabilize as upstream production capacity adjusts, with milk prices anticipated to recover gradually [4]. Summary by Sections 1. Market Performance - The food and beverage sector's performance last week was a decline of 1.06%, with soft drinks showing a notable increase of 9.27% [4][9]. - Top-performing stocks included Junyao Health and Kweichow Moutai, with gains of 38.58% and 32.17% respectively [4][9]. 2. Key Consumer Products and Raw Material Prices 2.1 Liquor Prices - As of June 1, 2025, the price for 2024 Moutai (bottle) is 2,070 CNY, down 50 CNY from the previous month [18]. 2.2 Beer Data - April production for major beer companies reached 2.896 million kiloliters, a 4.8% increase year-on-year [23]. 2.3 Upstream Raw Material Data - As of May 30, 2025, the price of fresh milk is 12.17 CNY per liter, with a year-on-year decrease of 0.49% [25]. 3. Industry Dynamics - Significant growth in wine sales was reported during the JD 618 shopping festival, with red wine sales increasing by 200% year-on-year [50]. - Guangdong province's beer production increased by 1.3% in the first four months of 2025 [50]. 4. Core Company Dynamics - Fuling Zhacai announced a cash dividend of 4.20 CNY per share, totaling 4.85 billion CNY [52]. - Haitian Flavoring announced a cash dividend of 8.60 CNY per share, totaling 47.73 billion CNY [52].

Investment Rating - The report provides a standard investment rating for the basic chemical industry, indicating a cautious outlook due to recent market fluctuations and supply chain disruptions [1]. Core Insights - Japan's Mitsui Chemicals is exiting the NF3 business, which may enhance China's competitiveness in electronic specialty gases, with potential market share expansion [4][10]. - The chlorantraniliprole incident has caused supply disruptions, potentially boosting the market for pesticides and intermediates, with a shift towards high-efficiency, low-toxicity products [4][12]. - The report suggests focusing on key sub-sectors such as integrated refining and petrochemical chains, refrigerant industry leaders, and domestic alternative materials [4][14]. Summary by Sections 1. Industry News and Event Commentary - Mitsui Chemicals' exit from the NF3 business is attributed to rising competition and costs, indicating that Chinese manufacturers may fill the gap and increase exports [10][11]. - The chlorantraniliprole incident is expected to accelerate market consolidation, benefiting companies with technological advantages and regulatory compliance [12][13]. 2. Chemical Sector Weekly Performance - For the week of May 26 to May 30, the Shanghai Composite Index fell by 1.08%, while the Shenwan Petroleum and Petrochemical Index rose by 0.40%, outperforming the market by 1.48 percentage points [15][18]. - The basic chemical index decreased by 0.66%, ranking 23rd among all Shenwan primary industries [15][18]. 3. Key Product Price and Spread Performance - Notable price increases included potassium chloride (up 5.66%) and paraxylene (up 4.94%), while hydrochloric acid saw a significant drop of 28.00% [27][28]. - The price spread for carbon black increased by 31.13%, indicating a tightening supply situation [29][30].

Investment Rating - The report provides a standard investment rating for the basic chemical industry, indicating a cautious outlook due to recent market fluctuations and supply chain disruptions [4]. Core Insights - The exit of Japan's Mitsui Chemicals from the nitrogen trifluoride (NF3) business is expected to enhance China's competitiveness in electronic specialty gases, with potential for increased market share [10][11]. - Supply disruptions from incidents like the chlorantraniliprole event are likely to boost the market outlook for pesticides and intermediates, leading to a potential price recovery in the short term [12][13]. - The report emphasizes the importance of monitoring key sub-sectors and suggests investment opportunities in integrated supply chains and leading companies within the chemical industry [14]. Summary by Sections 1. Industry News and Event Commentary - Mitsui Chemicals announced its exit from the NF3 business, with production ceasing by March 2026, indicating a shift in market dynamics favoring Chinese producers [10]. - A chemical company experienced an explosion, impacting the chlorantraniliprole supply chain, which may lead to a consolidation of market players and a potential price increase for certain pesticide products [12][13]. 2. Chemical Sector Weekly Performance - For the week of May 26 to May 30, the Shanghai Composite Index fell by 1.08%, while the Shenwan Petroleum and Petrochemical Index rose by 0.40%, outperforming the market [15]. - The basic chemical index decreased by 0.66%, ranking 23rd among all Shenwan primary industries [15]. 3. Key Product Price Movements - Notable price increases included potassium chloride (up 5.66%) and paraxylene (up 4.94%), while hydrochloric acid saw a significant drop of 28.00% [27][28]. - The report highlights the price fluctuations of key products, indicating a volatile market environment that could present both risks and opportunities for investors [27][28]. 4. Investment Recommendations - The report suggests focusing on integrated players in the refining-PX-PTA chain, leading fluorochemical companies, and firms in the domestic substitution of new materials [14]. - Specific companies highlighted for potential investment include Hengli Petrochemical, Rongsheng Petrochemical, and various leaders in the semiconductor materials sector [14].

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][37]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 2.21% in the week from May 26 to May 30, ranking second among 31 industries in the Shenwan index and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has risen by 6.61%, ranking sixth among the 31 industries and outperforming the CSI 300 index by 9.02 percentage points [4][13][15]. - The current PE valuation for the pharmaceutical and biotechnology sector is 27.98 times, which is at the historical median level, with a valuation premium of 137% compared to the CSI 300 index. The top three sub-sectors in terms of growth are chemical pharmaceuticals, biological products, and medical services, with increases of 3.83%, 3.14%, and 2.46% respectively [4][22][15]. - A total of 373 stocks (77.9%) in the sector rose last week, while 97 stocks (20.3%) declined. The top five gainers were Shuyou Shen (60.41%), Huason Pharmaceutical (41.97%), Changshan Pharmaceutical (35.91%), Huana Pharmaceutical (32.62%), and Yifang Biological (30.51%) [4][27]. Market Performance - The pharmaceutical and biotechnology sector's performance is highlighted by the approval of 11 innovative drugs by the National Medical Products Administration (NMPA) on May 29, which enhances treatment options for patients and showcases the increasing innovation capability of China's pharmaceutical industry [5][29]. - The 2025 American Society of Clinical Oncology (ASCO) annual meeting showcased several domestic innovative drug projects, indicating that local companies are gaining international recognition for their innovative capabilities [5][32]. Investment Recommendations - The report suggests focusing on the innovative drug sector as it is the most certain and leading sub-sector within the pharmaceutical and biotechnology industry. Additionally, it recommends exploring investment opportunities in medical devices, traditional Chinese medicine, chain pharmacies, and medical services [6][35]. - Recommended stocks include Beida Pharmaceutical, Te Bao Biological, Qianhong Pharmaceutical, Ling Rui Pharmaceutical, and Lao Bai Xing. Stocks to watch include Kelong Pharmaceutical, Rongchang Biological, Kaili Medical, Huaxia Eye Hospital, and Baipu Sais [6][35].

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][37]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 2.21% in the week from May 26 to May 30, ranking second among 31 industries in the Shenwan index and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has risen by 6.61%, ranking sixth among the 31 industries and outperforming the CSI 300 index by 9.02 percentage points [4][13][15]. - The current PE valuation for the pharmaceutical and biotechnology sector is 27.98 times, which is at the historical median level, with a valuation premium of 137% compared to the CSI 300 index. The top three sub-sectors in terms of growth are chemical pharmaceuticals, biological products, and medical services, with increases of 3.83%, 3.14%, and 2.46% respectively [4][22][15]. Summary by Sections Market Performance - The pharmaceutical and biotechnology sector's performance for the week of May 26 to May 30 was a 2.21% increase, ranking second among 31 industries, and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has increased by 6.61%, ranking sixth and outperforming the CSI 300 by 9.02 percentage points. The top three sub-sectors were chemical pharmaceuticals (3.83%), biological products (3.14%), and medical services (2.46%) [4][13][15]. Industry News - On May 29, the National Medical Products Administration (NMPA) approved 11 innovative drugs, with 9 being domestically developed, showcasing the increasing innovation capability of China's pharmaceutical industry. Additionally, during the 2025 American Society of Clinical Oncology (ASCO) annual meeting, significant clinical data was presented for various treatments, indicating the growing recognition of domestic innovative drug companies [5][29][32]. Investment Recommendations - The report suggests focusing on the innovative drug sector, which is seen as the most certain and leading sub-sector within the pharmaceutical and biotechnology industry. It also recommends exploring investment opportunities in medical devices, traditional Chinese medicine, chain pharmacies, and medical services. Specific stock recommendations include Beida Pharmaceutical, Teva Biopharma, Qianhong Pharmaceutical, Lingrui Pharmaceutical, and Lao Baixing, with additional stocks to watch including Kelun Pharmaceutical, Rongchang Biopharma, Kaili Medical, Huaxia Eye Hospital, and Baipusais [6][35].